首页> 美国卫生研究院文献>Journal of the Endocrine Society >OR15-03 High Prevalence of Gene Variants in Boys of Prepubertal Age with Clinical Suspicion of Central Hypogonadism and Low AMH
【2h】

OR15-03 High Prevalence of Gene Variants in Boys of Prepubertal Age with Clinical Suspicion of Central Hypogonadism and Low AMH

机译:15-03临床怀疑中非产后症和低AMH临床怀疑的青少年年龄段基因变异性高患病率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: In boys of prepubertal age, the diagnosis of central hypogonadism may be difficult to ascertain since gonadotropins and testosterone are normally low. Sertoli cell markers, like AMH and inhibin B, may be useful. In recent years, with the development of next generation sequencing (NGS) technology, the number of genes associated with central hypogonadism has had an exponential increase. However, even with these advanced techniques, the gene variants with potential pathogenicity can be found at present in only 30-50% of the patients. Hypothesis of the study: Low serum AMH is an appropriate screening biomarker to select patients for NGS, in order to make a genetic diagnosis in boys of prepubertal age with suspected central hypogonadism. Patients and methods: All patients aged 1-10 yr referred between 2001 and 2018 with clinical suspicion of central hypogonadism (micropenis and cryptorchidism and/or microorchidism), with low serum AMH (<10th centile) were included. Serum AMH was determined by ELISA (Beckman-Coulter), and LH, FSH and testosterone (T) by ECLIA (Roche). NGS was performed with the TruSight™ One Sequencing Panel in a NextSeq® 500 sequencer (Illumina). Results are expressed as medians (range). Results: 13 patients were included. Age at first visit was 4.4 (0.1-9.2) yr. Cryptorchidism was present in all of them, micropenis in 10 and microorchidism in 11. Orchiopexy was required in 11 boys and the other 2 responded to hCG treatment. 4 patients had olfactory disturbances, 1 had sensory deafness and 1 had piebaldism. 2 patients had a family history of olfactory disturbances and/or central hypogonadism. 7 patients could be followed up to pubertal age, and the diagnosis of central hypogonadism was clinically confirmed. At age 6.1 yr (1.2-10), AMH was 159 pmol/L (65-363), LH was <0.1 IU/L in all, FSH was 0.61 IU/L (<0.1-1.9). 17 variants in 9 genes associated with central hypogonadism were found in 10 of 13 patients. 5 boys had 1 gene variant, while 4 had 2 gene variants and 1 had 3 gene variants indicating probable oligogenicity, in the following genes: FGFR1 (n:4), CHD7 (n:3), PROKR2 (n:2), SOX10 (n:2), AXL (n:2), HS6ST1 (n:1), AMHR2 (n:1), NSMF (n:1), DCC (n:1). Conclusion: A high prevalence of gene variants was found in boys of prepubertal age with a suspicion of central hypogonadism based on micropenis and cryptorchidism and/or microorchidism with low serum AMH.
机译:简介:在预接种年龄的男孩中,由于促性腺激素和睾酮通常是低的,因此可能难以确定中央性腺后性腺的诊断。 Sertoli细胞标志物,如AMH和抑制剂B,可能是有用的。近年来,随着下一代测序(NGS)技术的发展,与中原相关的基因数量具有指数增加。然而,即使通过这些先进的技术,具有潜在致病性的基因变体也可以仅在30-50%的患者中发现。该研究的假设:低血清AMH是适当的筛查生物标志物,用于选择患者NGS,以便在具有疑似中性腺增多症的预接种年龄的男孩中进行遗传诊断。患者和方法:2001年至2018年患者的所有患者1-10岁,临床暂停中央性腺性腺(微直接和密码症和/或微型趋势),包括低血清AMH(<第10厘升)。血清AMH由ELISA(Beckman-Coulter)和LH,FSH和睾酮(T)由Eclia(Roche)测定。 NGS在NextSeq®500序列仪(Illumina)中使用Trusight™ONE测序面板进行。结果表示为中位数(范围)。结果:包括13名患者。第一次访问的年龄是4.4(0.1-9.2)。在所有这些中存在密码刺激,10个细胞,11种Microorchidism 11. 11个男孩,其他2次响应HCG治疗,需要占毒素。 4名患者有嗅觉紊乱,1人感觉到耳聋,1人有皮屑。 2名患者具有嗅觉紊乱和/或中央性腺的家族史。 7例患者可以随访普及塔尔年龄,临床上证实了中共亢的诊断。在6.1岁时(1.2-10),AMH为159 pmol / L(65-363),LH为<0.1 IU / L,FSH为0.61 IU / L(<0.1-1.9)。在13名患者的10例中发现了与中共亢性相关的9个基因中的17种变体。 5男孩有1个基因变体,而4具有2个基因变体,1具有3个基因变体,表明可能的寡核酸性能,在以下基因中:FGFR1(N:4),CHD7(N:3),PROKR2(N:2),SOX10 (N:2),AXL(N:2),HS6ST1(N:1),AMHR2(N:1),NSMF(N:1),DCC(N:1)。结论:基于微直接和密码刺激和低血清AMH的微生物和密码刺激和/或微型趋势,在预接种年龄的男孩中发现了基因变异的高患病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号